Michael Zdanowski - Feb 1, 2022 Form 4 Insider Report for Talaris Therapeutics, Inc. (TALS)

Role
Chief Technology Officer
Signature
/s/ Mary Kay Fenton, attorney-in-fact
Stock symbol
TALS
Transactions as of
Feb 1, 2022
Transactions value $
$19,110
Form type
4
Date filed
2/2/2022, 05:00 PM
Next filing
Sep 13, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TALS Common Stock Award $19.1K +1.47K $13.00 1.47K Dec 31, 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TALS Stock Option (Right to Buy) Award $0 +200K $0.00 200K Feb 1, 2022 Common Stock 200K $9.10 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares were acquired by the reporting individual under the issuer's 2021 Employee Stock Purchase Plan ("ESPP") in a transaction exempt under Rule 16b-3(c).
F2 The shares underlying this option shall vest as follows: 25% shall vest on February 1, 2023; and the remaining shall vest in 36 equal monthly installments thereafter.